Femasys Inc (FEMY NASDAQ) stock market data APIs
$1.1307
0.03(2.7%)
as of May 6, 2025
Femasys Inc Financial Data Overview
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. Its product candidate, FemBloc, is a non-surgical permanent birth control solution. It offers its products to reproductive endocrinologists for infertility products, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Prev. Close
1.1307
Open
1.1584
High
1.214
Low
1.0989
52 wk Range
0.86-1.8
Market Cap
31 494 K
Shares Outstanding
27 150 K
Revenue
1 629 K
EPS
-0.23
Beta
-2.549
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Femasys Inc data using free add-ons & libraries
Get Femasys Inc Fundamental Data
Femasys Inc Fundamental data includes:
- Net Revenue: 1 629 K
- EBITDA: -17 488 488
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-27
- EPS/Forecast: -0.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Femasys Inc News
New
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 202...
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of ...
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of dis...
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (G...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
